<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6245">
  <stage>Registered</stage>
  <submitdate>29/04/2015</submitdate>
  <approvaldate>29/04/2015</approvaldate>
  <nctid>NCT02441283</nctid>
  <trial_identification>
    <studytitle>A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530</studytitle>
    <scientifictitle>A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-000452-24</secondaryid>
    <secondaryid>M13-576</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-493
Treatment: drugs - ABT-530

Other: All subjects enrolled in the study - Follow up study that includes sample collection (diagnostic intervention) procedures only and no treatment


Treatment: drugs: ABT-493
Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.

Treatment: drugs: ABT-530
Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of subjects who maintain a sustained virologic response - Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification.</outcome>
      <timepoint>Up to 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assessing persistence of resistance-associated amino acid variants - It will be assessed by population, deep, and/or clonal nucleotide sequencing.</outcome>
      <timepoint>Up to 3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of medical events related to the progression of liver disease - Summarize medical events related to progression of liver disease including events of hepatic decompensation, change in Child-Pugh classification, liver transplantation, hepatocellular carcinoma, and/or death.</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participant FibroTest Score - A biomarker test that used blood serum to generate a score that correlates to the degree of liver damage in participants</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participant Aspartate transaminase to platelet ratio index (APRI) - The aspartate transaminase to platelet ratio index (APRI) is used to assess liver fibrosis in participants with chronic liver disease</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participant IP-10 results - IP-10 is used to assess liver fibrosis in participants with chronic liver disease</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participant FibroScan and/or liver biopsy results, if available - The FibroScan and/or liver biopsy are used to assess liver fibrosis in participants with chronic liver disease</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participant alpha fetoprotein results - Alpha fetoprotein is used to assess for liver disease in participants with chronic HCV</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. The subject is male or female 18 years of age or older

          2. The subject has received at least one dose of an ABT-493- and/or ABT 530 containing
             regimen in a prior AbbVie HCV Phase 2 or 3 study

          3. The interval between the last dose of the AbbVie DAA therapy from the previous
             clinical study and enrollment in Study M13-576 must be no longer than 2 years.

          4. The subject must voluntarily sign and date the informed consent form approved by an
             Independent Review Board or Ethics Committee prior to the initiation of any
             study-specific procedures.

          5. Subject completed the post-treatment period of an eligible prior study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. The investigator considers the subject unsuitable for the study for any reasons (e.g.,
             failure to comply with study procedures in the prior AbbVie clinical study).

          2. Receipt of any investigational HCV antiviral treatment after receiving ABT-493 and/or
             ABT-530 in the prior study.

          3. Subjects who experienced non-virologic treatment failure due to premature
             discontinuation of study drug in prior study of ABT-493/ABT-530.

          4. Participation in AbbVie's Study M15-942 protocol for re-treatment for virologic
             failure in the prior Phase 2 or 3 study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>22/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>13/07/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital /ID# 155391 - Adelaide</hospital>
    <hospital>St. Vincent's Hospital /ID# 155395 - Darlinghurst</hospital>
    <hospital>St. Vincents Hospital /ID# 155394 - Fitzroy</hospital>
    <hospital>Royal Brisbane and Womens Hospital /ID# 155396 - Herston</hospital>
    <hospital>Royal Melbourne Hospital /ID# 155393 - Parkville</hospital>
    <hospital>Westmead Hospital /ID# 155392 - Westmead</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>NSW 2010 - Darlinghurst</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>QLD 4029 - Herston</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>2145 - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>DÃ¼sseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Bayamon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ponce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Santurce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a rollover study to assess resistance and durability of response to ABT-493 and/or
      ABT-530 in subjects who have participated in Phase 2 or 3 clinical studies with these agents
      for the treatment of chronic HCV.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02441283</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Pugatch, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>